Terms: = Ovarian cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
29 results:
1. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.
Dong L; Wang T; Li N; Yao H; Ying J; Wu L; Yuan G
Cells; 2022 Nov; 11(22):. PubMed ID: 36428992
[TBL] [Abstract] [Full Text] [Related]
4. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
5. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract] [Full Text] [Related]
6. Genomic landscape of endometrial carcinomas of no specific molecular profile.
Momeni-Boroujeni A; Nguyen B; Vanderbilt CM; Ladanyi M; Abu-Rustum NR; Aghajanian C; Ellenson LH; Weigelt B; Soslow RA
Mod Pathol; 2022 Sep; 35(9):1269-1278. PubMed ID: 35365770
[TBL] [Abstract] [Full Text] [Related]
7. [Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism].
Feng TF; Yao DM; Zheng R; Jiang DS; Zhang LL; Xing Q; Li L
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):139-146. PubMed ID: 35184457
[No Abstract] [Full Text] [Related]
8. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
9. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
[TBL] [Abstract] [Full Text] [Related]
11. The Prevalence, Associated Factors for Lung Metastases Development and prognosis in ovarian Serous cancer Based on SEER Database.
Cao C; Yang X
Technol Cancer Res Treat; 2020; 19():1533033820983801. PubMed ID: 33356997
[TBL] [Abstract] [Full Text] [Related]
12. Ancestry-specific predisposing germline variants in cancer.
Oak N; Cherniack AD; Mashl RJ; ; Hirsch FR; Ding L; Beroukhim R; Gümüş ZH; Plon SE; Huang KL
Genome Med; 2020 May; 12(1):51. PubMed ID: 32471518
[TBL] [Abstract] [Full Text] [Related]
13. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in cancer.
Wu Z; Li S; Tang X; Wang Y; Guo W; Cao G; Chen K; Zhang M; Guan M; Yang D
Theranostics; 2020; 10(9):3939-3951. PubMed ID: 32226530
[No Abstract] [Full Text] [Related]
14. MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting atm.
Liu HY; Zhang YY; Zhu BL; Feng FZ; Zhang HT; Yan H; Zhou B
J Ovarian Res; 2019 Jul; 12(1):60. PubMed ID: 31277702
[TBL] [Abstract] [Full Text] [Related]
15. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract] [Full Text] [Related]
16. Role of Genetic Testing for Inherited Prostate cancer Risk: Philadelphia Prostate cancer Consensus Conference 2017.
Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
[TBL] [Abstract] [Full Text] [Related]
17. PARP Inhibitors in the Treatment of Triple-Negative Breast cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of E-cadherin with STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different ER-alpha immunoprofile.
Sulkowska U; Wincewicz A; Kanczuga-Koda L; Koda M; Sulkowski S
Gynecol Endocrinol; 2018 Feb; 34(2):171-174. PubMed ID: 28937296
[TBL] [Abstract] [Full Text] [Related]
19. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Guffanti F; Fruscio R; Rulli E; Damia G
Sci Rep; 2016 Dec; 6():38142. PubMed ID: 27905519
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract] [Full Text] [Related]
[Next]
